Results 41 to 50 of about 10,548 (182)

Heart-Failing Jehovah's Witness Patient Successfully Treated by Minimally Invasive LVAD Implantation without Any Blood Transfusions

The Thoracic & Cardiovascular Surgeon Reports, 2015
Left ventricular assist device (LVAD) implantation without the use of any blood products is considered as a challenge. We present a 48-year-old patient (175 cm, 75 kg, body mass index 24.5 kg/m2) who was admitted to our clinic due to end-stage heart ...
Jasmin S. Hanke, Murat Avsar, Axel Haverich, Jan D. Schmitto   +3 more
doaj   +1 more source

Ablation of ventricular tachycardia in a patient with a left ventricular assist device

Türk Kardiyoloji Derneği Arşivi, 2020
The use of a left ventricular assist device (LVAD) as a bridge to heart transplantation (HTx) or as a destination therapy in patients with a contraindication for HTx is increasing.
Evrim Şimşek, Emin Evren Özcan, Emre Demir, Pelin Öztürk, Sanem Nalbantgil   +4 more
doaj   +1 more source

Prognostic Value of Natriuretic Peptides for All-Cause Mortality, Right Ventricular Failure, Major Adverse Events, and Myocardial Recovery in Advanced Heart Failure Patients Receiving a Left Ventricular Assist Device: A Systematic Review

Frontiers in Cardiovascular Medicine, 2021
Aims: Major adverse event (MAE) rates during left ventricular assist device (LVAD) therapy in advanced heart failure (HF) patients are high, and impair quality of life and survival.
Eva Janssen, J. Wouter Jukema, Saskia L. M. A. Beeres, Martin J. Schalij, Laurens F. Tops   +4 more
doaj   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non‐hospital settings in the community

ESC Heart Failure, 2021
The accepted use of left ventricular assist device (LVAD) technology as a good alternative for the treatment of patients with advanced heart failure together with the improved survival of the LVAD‐supported patients on the device and the scarcity of ...
Binyamin Ben Avraham, Marisa Generosa Crespo‐Leiro, Gerasimos Filippatos, Israel Gotsman, Petar Seferovic, Tal Hasin, Luciano Potena, Davor Milicic, Andrew J.S. Coats, Giuseppe Rosano, Frank Ruschitzka, Marco Metra, Stefan Anker, Johann Altenberger, Stamatis Adamopoulos, Yaron D. Barac, Ovidiu Chioncel, Nicolaas De Jonge, Jeremy Elliston, Maria Frigeiro, Eva Goncalvesova, Avishay Grupper, Righab Hamdan, Yoav Hammer, Loreena Hill, Osnat Itzhaki Ben Zadok, Miriam Abuhazira, Jacob Lavee, Wilfried Mullens, Sanemn Nalbantgil, Massimo F. Piepoli, Piotr Ponikowski, Arsen Ristic, Arjang Ruhparwar, Aviv Shaul, Laurens F. Tops, Steven Tsui, Stephan Winnik, Tiny Jaarsma, Finn Gustafsson, Tuvia Ben Gal   +40 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Validity and reliability of the left ventricular assist device self-care behaviour scale.

PLoS ONE, 2023
BackgroundAdequate self-care behaviour is essential for patients with a left ventricular assist device (LVAD) to prevent complications, prolong life, and optimise quality of life. However, there were no valid and reliable measurements available to assess
Naoko P Kato, Semyon Melnikov, Quin E Denfeld, Jesus Casida, Anna Strömberg, Tuvia Ben-Gal, Christopher S Lee, Tiny Jaarsma   +7 more
doaj   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source